Alexion Pharmaceuticals, Inc. announced today that researchers will present new functional and quality-of-life data from clinical studies in children with hypophosphatasia who were treated with asfotase alfa for at least three years at the Endocrine Society's 97th Annual Meeting and Expo . Researchers will also present data from two patient-reported surveys characterizing the burden of HPP in adults.